Wedbush Morgan Reiterates a 'Buy' Rating on ImmunoGen (IMGN); Positive Surprise From License Agreement
Tweet Send to a Friend
Wedbush Morgan reiterates a 'Buy' rating on ImmunoGen (Nasdaq: IMGN). Price target $10.
Wedbush analyst says, "ImmunoGen announced yesterday that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "ImmunoGen announced yesterday that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
